Antibodies in maternal sera and their associations with MR/DPD in the offspring
| Neuropsychiatric/developmental diagnosis of children | Fisher’s p value | ||
| MR/DPD | No MR/DPD | ||
| Positive/Total (%) | Positive/Total (%) | ||
| Cohort A: mothers with subsequent psychosis and individually matched control mothers | |||
| Either antibody | 5/11 (45.5) | 9/176 (5.1) | 0.0004 |
| CASPR2-Ab | 1/11 (9.1) | 2/176 (1.1) | 0.17 |
| NMDAR-Ab | 4/11 (36.0) | 7/176 (4.0) | 0.00518 |
| Cohort B: mothers of children with mental retardation and other disorders of psychological development and individually matched control mothers | |||
| CASPR2-Ab | 7/171 (4.1) | 1/171 (0.6) | 0.067 |
| NMDAR-Ab | 10/171 (5.8) | 9/171 (5.3) | >0.99 |
| Combined analysis | |||
| CASPR2-Ab | 8/182 (4.4) | 3/347 (0.9) | 0.01 |
| NMDAR-Ab | 14/182 (7.7) | 16/347 (4.6) | 0.17 |
MR/DPD as defined here includes children with a mild or unspecified mental retardation with or without impairment of behaviour, specific developmental disorders of scholastic skills or other disorders of psychological development.
CASPR2, contactin-associated protein-like 2; MR/DPD, mental retardation and/or disorders of psychological development; NMDAR, N-methyl-D-aspartate receptor. Significant p values are in bold.